A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies.

Drug Category : Array
Conference Category : Array
Lead Author : Savona M, Patel M, et al.
Published Date : 10/12/2013
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASH2013Poster4373.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top